Asian Pacific Journal of Cancer Prevention

Asian Pacific Journal of Cancer Prevention (아시아태평양암예방학회)
권호 표지
DOI QR코드

DOI QR Code

PDCD4 as a Predictor of Sensitivity to Neoadjuvant Chemoradiotherapy in Locally Advanced Rectal Cancer Patients

  • Dou, Xue (Department of Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong Academy of Medical Sciences, University of Jinan) ;
  • Wang, Ren-Ben (Department of Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong Academy of Medical Sciences, University of Jinan) ;
  • Meng, Xiang-Jiao (Department of Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong Academy of Medical Sciences, University of Jinan) ;
  • Yan, Hong-Jiang (Department of Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong Academy of Medical Sciences, University of Jinan) ;
  • Jiang, Shu-Mei (Department of Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong Academy of Medical Sciences, University of Jinan) ;
  • Zhu, Kun-Li (Department of Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong Academy of Medical Sciences, University of Jinan) ;
  • Xu, Xiao-Qing (Department of Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong Academy of Medical Sciences, University of Jinan) ;
  • Chen, Dong (Department of Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong Academy of Medical Sciences, University of Jinan) ;
  • Song, Xian-Rang (Shandong Provincial Key Laboratory of Radiation Oncology, Shandong Academy of Medical Sciences, University of Jinan) ;
  • Mu, Dian-Bin (Department of Pathology, Shandong Cancer Hospital and Institute, Shandong Academy of Medical Sciences, University of Jinan)
  • Published : 2014.01.30
Download PDF
⟨ Previous Next ⟩

Abstract

Objective: The purpose of this study was to examine the role of programmed cell death 4 (PDCD4) expression in predicting tumor response to neoadjuvant chemoradiotherapy and outcomes for patients with locally advanced rectal cancer. Methods: Clinicopathological factors and expression of PDCD4 were evaluated in 92 patients with LARC treated with nCRT. After the completion of therapy, 4 cases achieved clinical complete response (cCR), and thus the remaining 88 patients underwent a standardized total mesorectal excision procedure. There were 38 patients (41.3%) with a good response (TRG 3-4) and 54 (58.7%) with a poor one (TRG 0-2). Results: Immunohistochemical staining analyses showed that patients with high expression of PDCD4 were more sensitive to nCRT than those with low PDCD4 expression (P=0.02). High PDCD4 expression before nCRT and good response (TRG3-4) were significantly associated with improved 5-year disease-free survival and 5-year overall survival (P<0.05). Multivariate analysis demonstrated that the pretreatment PDCD4 expression was an independent prognostic factor. Conclusion: Our study demonstrated that high expression of PDCD4 protein is a useful predictive factor for good tumor response to nCRT and good outcomes in patients with LARC.

Keywords

References

  1. Afonja O, Juste D, Das S, Matsuhashi S, Samuels HH (2004). Induction of PDCD4 tumor suppressor gene expression by RAR agonists, antiestrogen and HER-2/neu antagonist in breast cancer cells. Evidence for a role in apoptosis. Oncogene, 23, 8135-45. https://doi.org/10.1038/sj.onc.1207983
  2. Anastasov N, Hofig I, Vasconcellos IG, et al (2012). Radiation resistance due to high expression of miR-21 and G2/M checkpoint arrest in breast cancer cells. Radiat Oncol, 7, 206. https://doi.org/10.1186/1748-717X-7-206
  3. Bitomsky N, Wethkamp N, Marikkannu R, Klempnauer KH (2008). siRNA-mediated knockdown of Pdcd4 expression causes upregulation of p21(Waf1/Cip1) expression. Oncogene, 27, 4820-9. https://doi.org/10.1038/onc.2008.115
  4. Bosset JF, Collette L, Calais G, et al (2006). Chemotherapy with preoperative radiotherapy in rectal cancer. N Engl J Med, 355, 1114-23. https://doi.org/10.1056/NEJMoa060829
  5. Chang KH, Miller N, Kheirelseid EA, et al (2011). MicroRNA-21 and PDCD4 expression in colorectal cancer. Eur J Surg Oncol, 37, 597-603. https://doi.org/10.1016/j.ejso.2011.04.001
  6. Chao TF, Xiong HH, Liu W, Chen Y, Zhang JX (2013). MiR-21 mediates the radiation resistance of glioblastoma cells by regulating PDCD4 and hMSH2. J Huazhong Univ Sci Technolog Med Sci, 33, 525-9. https://doi.org/10.1007/s11596-013-1153-4
  7. Chen Y, Liu W, Chao T, et al (2008). MicroRNA-21 downregulates the expression of tumor suppressor PDCD4 in human glioblastoma cell T98G. Cancer Lett, 272, 197-205. https://doi.org/10.1016/j.canlet.2008.06.034
  8. Cmarik JL, Min H, Hegamyer G, et al (1999). Differentially expressed protein Pdcd4 inhibits tumor promoter-induced neoplastic trans-formation. Proc Natl Acad Sci USA, 96, 14037-42. https://doi.org/10.1073/pnas.96.24.14037
  9. Dorrello NV, Peschiaroli A, Guardavaccaro D, et al (2006). S6K1- and betaTRCP-mediated degradation of PDCD4 promotes protein translation and cell growth. Science, 314, 467-71. https://doi.org/10.1126/science.1130276
  10. Dworak O, Keilholz L, Hoffmann A (1997). Pathological features of rectal cancer after preoperative radiochemotherapy. Int J Colorectal Dis, 12, 19-23. https://doi.org/10.1007/s003840050072
  11. Gerard JP, Conroy T, Bonnetain F, et al (2006). Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: results of FFCD 9203. J Clin Oncol, 24, 4620-5. https://doi.org/10.1200/JCO.2006.06.7629
  12. Horiuchi A, Iinuma H, Akahane T, Shimada R, Watanabe T (2012). Prognostic significance of PDCD4 expression and association with microRNA-21 in each Dukes' stage of colorectal cancer patients. Oncol Rep, 27, 1384-92.
  13. Horsman MR, Bohm L, Margison GP, et al (2006). Tumor radiosensitizers--current status of development of various approaches: report of an International Atomic Energy Agency meeting. Int J Radiat Oncol Biol Phys, 64, 551-61. https://doi.org/10.1016/j.ijrobp.2005.09.032
  14. Kheirelseid EA, Miller N, Chang KH, Nugent M, Kerin MJ (2013). Clinical applications of gene expression in colorectal cancer. J Gastrointest Oncol, 4, 144-57.
  15. Kim IJ, Lim SB, Kang HC, et al (2007). Microarray gene expression profiling for predicting complete response to preoperative chemoradiotherapy in patients with advanced rectal cancer. Dis Colon Rectum, 50, 1342-53. https://doi.org/10.1007/s10350-007-277-7
  16. Lim SC, Hong R (2011). Programmed cell death 4 (Pdcd4) expression in colorectal adenocarcinoma: Association with clinical stage. Oncol Lett, 2, 1053-7.
  17. Mudduluru G, Medved F, Grobholz R, et al (2007). Loss of programmed cell death 4 expression marks adenomacarcinoma transition, correlates inversely with phosphorylated protein kinase B, and is an independent prognostic factor in resected colorectal cancer. Cancer, 110, 1697-707. https://doi.org/10.1002/cncr.22983
  18. Onishi Y, Kizaki H (1996). Molecular cloning of the genes suppressed in RVC lympuhoma cells by topoisomerase inhibitors. Biochem Biophys Res Commun, 228, 7-13. https://doi.org/10.1006/bbrc.1996.1609
  19. Palamarchuk A, Efanov A, Maximov V, Aqeilan RI, Croce CM (2005). Pekarsky: Akt phosphorylates and regulates Pdcd4 tumor suppressor protein. Cancer Res, 65, 11282-6. https://doi.org/10.1158/0008-5472.CAN-05-3469
  20. Rodel C, Martus P, Papadoupolos T, et al (2005). Prognostic significance of tumor regression after preoperative chemoradiotherapy for rectal cancer. J Clin Oncol, 23, 8688-96. https://doi.org/10.1200/JCO.2005.02.1329
  21. Sanghera P, Wong DW, Mcconkey CC, Geh JI, Hartley A (2008). Chemoradiotherapy for rectal cancer: an updated analysis of factors affecting pathological response. Clin Oncol (R Coll Radiol), 20, 176-83. https://doi.org/10.1016/j.clon.2007.11.013
  22. Sauer R, Becker H, Hohenberger W, et al (2004). Preoperative versus postoperative chemoradiotherapy for rectal cancer. N Engl J Med, 351,1731-40. https://doi.org/10.1056/NEJMoa040694
  23. Schlichter U, Burk O, Worpenberg S, Klempnauer KH (2001). The chicken Pdcd4 gene is regulated by v-Myb. Oncogene, 20, 231-9. https://doi.org/10.1038/sj.onc.1204071
  24. Shibahara K, Asano M, Ishida Y, et al (1995). Isolation of a novel mouse gene MA- 3 that is induced upon programmed cell death. Gene, 166, 297-301. https://doi.org/10.1016/0378-1119(95)00607-9
  25. Soejima H, Miyoshi O, Yoshinagaga H, et al (1999). Assignment of the programmed cell death 4 gene (PDCD4) to human chromosome band 10q24 by in situ hybridization. Cytogenet Cell Genet, 87, 113-4. https://doi.org/10.1159/000015408
  26. Suarez J, Vera R, Balen E, et al (2008). Pathologic response assessed by Mandard grade is a better prognostic factor than down staging for disease-free survival after preoperative radiochemotherapy for advanced rectal cancer. Colorectal Dis, 10, 563-8. https://doi.org/10.1111/j.1463-1318.2007.01424.x
  27. Supiot S, Gouraud W, Campion L, et al (2013). Early dynamic transcriptomic changes during preoperative radiotherapy in patients with rectal cancer: a feasibility study. World J Gastroenterol, 19, 3249-54. https://doi.org/10.3748/wjg.v19.i21.3249
  28. Vecchio FM, Valentini V, Minsky BD, et al (2005). The relationship of pathologic tumor regression grade (TRG) and outcomes after preoperative therapy in rectal cancer. Int J Radiat Oncol Biol Phys, 62, 752-60. https://doi.org/10.1016/j.ijrobp.2004.11.017
  29. Wang WQ, Zhang H, Wang HB, et al (2010). Programmed cell death 4 (PDCD4) enhances the sensitivity of gastric cancer cells to TRAIL-induced apoptosis by inhibiting the PI3K/ Akt signaling pathway. Mol Diagn Ther, 14, 155-61. https://doi.org/10.1007/BF03256368
  30. Woodard J, Sassano A, Hay N, Platanias LC (2008). Statindependent suppression of the Akt/mammalian target of rapamycin signaling cascade and programmed cell death 4 up-regulation in renal cell carcinoma. Clin Cancer Res, 14, 4640-9. https://doi.org/10.1158/1078-0432.CCR-07-5232
  31. Zhang H, Ozaki I, Mizuta T, et al (2006). Involvement of programmed cell death 4 in transforming growth factorbeta1- induced apoptosis in human hepatocellular carcinoma. Oncogene, 25, 6101-12. https://doi.org/10.1038/sj.onc.1209634
  32. Zhang X, Wang X, Song X, et al (2010). Programmed cell death 4 enhances chemosensitivity of ovarian cancer cells by activating death receptor pathway in vitro and in vivo. Cancer Sci, 101, 2163-70. https://doi.org/10.1111/j.1349-7006.2010.01664.x
  33. Zhang Z, Dubois R (2001). Detection of differentially expressed genes in human colon carcinoma cells treated with a selective COX-2 inhibitor. Oncogene, 20, 4450-6. https://doi.org/10.1038/sj.onc.1204588

Cited by

  1. Carbohydrate Antigen 19-9 Levels Associated with Pathological Responses to Preoperative Chemoradiotherapy in Rectal Cancer vol.15, pp.13, 2014, https://doi.org/10.7314/APJCP.2014.15.13.5383
  2. The clinical association of programmed cell death protein 4 (PDCD4) with solid tumors and its prognostic significance: a meta-analysis vol.35, pp.1, 2016, https://doi.org/10.1186/s40880-016-0158-3
  3. Molecular profiling of locally-advanced rectal adenocarcinoma using microRNA expression (Review) vol.51, pp.2, 2017, https://doi.org/10.3892/ijo.2017.4045